Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 519

1.

Cell free circulating tumor nucleic acids, a revolution in personalized cancer medicine.

Kerachian MA, Poudineh A, Thiery JP.

Crit Rev Oncol Hematol. 2019 Dec;144:102827. doi: 10.1016/j.critrevonc.2019.102827. Epub 2019 Nov 2. Review.

PMID:
31715326
2.

Author Correction: c-Met activation leads to the establishment of a TGFβ-receptor regulatory network in bladder cancer progression.

Sim WJ, Iyengar PV, Lama D, Lui SKL, Ng HC, Haviv-Shapira L, Domany E, Kappei D, Tan TZ, Saei A, Jaynes PW, Verma CS, Kumar AP, Rouanne M, Ha HK, Radulescu C, Ten Dijke P, Eichhorn PJA, Thiery JP.

Nat Commun. 2019 Nov 8;10(1):5148. doi: 10.1038/s41467-019-13095-4.

3.

Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer.

Recondo G, Mezquita L, Facchinetti F, Planchard D, Gazzah A, Bigot L, Rizvi AZ, Frias RL, Thiery JP, Scoazec JY, Sourisseau T, Howarth K, Deas O, Samofalova D, Galissant J, Tesson P, Braye F, Naltet C, Lavaud P, Mahjoubi L, Abou Lovergne A, Vassal G, Bahleda R, Hollebecque A, Nicotra C, Ngo-Camus M, Michiels S, Lacroix L, Richon C, Auger N, De Baere T, Tselikas L, Solary E, Angevin E, Eggermont AM, Andre F, Massard C, Olaussen KA, Soria JC, Besse B, Friboulet L.

Clin Cancer Res. 2019 Oct 4. doi: 10.1158/1078-0432.CCR-19-1104. [Epub ahead of print]

PMID:
31585938
4.

Traditional Chinese Medicine and regulatory roles on epithelial-mesenchymal transitions.

Bai J, Kwok WC, Thiery JP.

Chin Med. 2019 Sep 23;14:34. doi: 10.1186/s13020-019-0257-6. eCollection 2019. Review.

5.

c-Met activation leads to the establishment of a TGFβ-receptor regulatory network in bladder cancer progression.

Sim WJ, Iyengar PV, Lama D, Lui SKL, Ng HC, Haviv-Shapira L, Domany E, Kappei D, Tan TZ, Saei A, Jaynes PW, Verma CS, Kumar AP, Rouanne M, Ha HK, Radulescu C, Ten Dijke P, Eichhorn PJA, Thiery JP.

Nat Commun. 2019 Sep 25;10(1):4349. doi: 10.1038/s41467-019-12241-2. Erratum in: Nat Commun. 2019 Nov 8;10(1):5148.

6.

AXL Targeting Overcomes Human Lung Cancer Cell Resistance to NK- and CTL-Mediated Cytotoxicity.

Terry S, Abdou A, Engelsen AST, Buart S, Dessen P, Corgnac S, Collares D, Meurice G, Gausdal G, Baud V, Saintigny P, Lorens JB, Thiery JP, Mami-Chouaib F, Chouaib S.

Cancer Immunol Res. 2019 Nov;7(11):1789-1802. doi: 10.1158/2326-6066.CIR-18-0903. Epub 2019 Sep 5.

PMID:
31488404
7.

Upregulation of PD-L1 expression in breast cancer cells through the formation of 3D multicellular cancer aggregates under different chemical and mechanical conditions.

Azadi S, Aboulkheyr Es H, Razavi Bazaz S, Thiery JP, Asadnia M, Ebrahimi Warkiani M.

Biochim Biophys Acta Mol Cell Res. 2019 Dec;1866(12):118526. doi: 10.1016/j.bbamcr.2019.118526. Epub 2019 Aug 6.

PMID:
31398408
8.

PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein.

Thura M, Al-Aidaroos AQ, Gupta A, Chee CE, Lee SC, Hui KM, Li J, Guan YK, Yong WP, So J, Chng WJ, Ng CH, Zhou J, Wang LZ, Yuen JSP, Ho HSS, Yi SM, Chiong E, Choo SP, Ngeow J, Ng MCH, Chua C, Yeo ESA, Tan IBH, Sng JXE, Tan NYZ, Thiery JP, Goh BC, Zeng Q.

Nat Commun. 2019 Jun 6;10(1):2484. doi: 10.1038/s41467-019-10127-x.

9.

SNAI1 recruits HDAC1 to suppress SNAI2 transcription during epithelial to mesenchymal transition.

Sundararajan V, Tan M, Tan TZ, Ye J, Thiery JP, Huang RY.

Sci Rep. 2019 Jun 5;9(1):8295. doi: 10.1038/s41598-019-44826-8.

10.

Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer through reduced expression of SDHC.

Røsland GV, Dyrstad SE, Tusubira D, Helwa R, Tan TZ, Lotsberg ML, Pettersen IKN, Berg A, Kindt C, Hoel F, Jacobsen K, Arason AJ, Engelsen AST, Ditzel HJ, Lønning PE, Krakstad C, Thiery JP, Lorens JB, Knappskog S, Tronstad KJ.

Cancer Metab. 2019 Jun 1;7:6. doi: 10.1186/s40170-019-0197-8. eCollection 2019.

11.

Circulating Tumor Cell cluster phenotype allows monitoring response to treatment and predicts survival.

Balakrishnan A, Koppaka D, Anand A, Deb B, Grenci G, Viasnoff V, Thompson EW, Gowda H, Bhat R, Rangarajan A, Thiery JP, Govind Babu K, Kumar P.

Sci Rep. 2019 May 28;9(1):7933. doi: 10.1038/s41598-019-44404-y.

12.

Phosphoproteomic Profiling Identifies Aberrant Activation of Integrin Signaling in Aggressive Non-Type Bladder Carcinoma.

Deb B, Puttamallesh VN, Gondkar K, Thiery JP, Gowda H, Kumar P.

J Clin Med. 2019 May 17;8(5). pii: E703. doi: 10.3390/jcm8050703.

13.

Probing compression versus stretch activated recruitment of cortical actin and apical junction proteins using mechanical stimulations of suspended doublets.

Gao X, Acharya BR, Engl WCO, De Mets R, Thiery JP, Yap AS, Viasnoff V.

APL Bioeng. 2018 Jun 19;2(2):026111. doi: 10.1063/1.5025216. eCollection 2018 Jun.

14.

Epithelial-to-mesenchymal transition: lessons from development, insights into cancer and the potential of EMT-subtype based therapeutic intervention.

Antony J, Thiery JP, Huang RY.

Phys Biol. 2019 May 7;16(4):041004. doi: 10.1088/1478-3975/ab157a. Review.

PMID:
30939460
15.

Mesenchymal-epithelial transition in development and reprogramming.

Pei D, Shu X, Gassama-Diagne A, Thiery JP.

Nat Cell Biol. 2019 Jan;21(1):44-53. doi: 10.1038/s41556-018-0195-z. Epub 2019 Jan 2. Review.

PMID:
30602762
16.

The prognostic significance of circulating tumor cells in head and neck and non-small-cell lung cancer.

Kulasinghe A, Kapeleris J, Kimberley R, Mattarollo SR, Thompson EW, Thiery JP, Kenny L, O'Byrne K, Punyadeera C.

Cancer Med. 2018 Dec;7(12):5910-5919. doi: 10.1002/cam4.1832. Epub 2018 Nov 22.

17.

The FZD7-TWIST1 axis is responsible for anoikis resistance and tumorigenesis in ovarian carcinoma.

Tan M, Asad M, Heong V, Wong MK, Tan TZ, Ye J, Kuay KT, Thiery JP, Scott C, Huang RY.

Mol Oncol. 2019 Apr;13(4):757-780. doi: 10.1002/1878-0261.12425. Epub 2019 Jan 19.

18.

A combined microfluidic-transcriptomic approach to characterize the extravasation potential of cancer cells.

Bersini S, Miermont A, Pavesi A, Kamm RD, Thiery JP, Moretti M, Adriani G.

Oncotarget. 2018 Nov 16;9(90):36110-36125. doi: 10.18632/oncotarget.26306. eCollection 2018 Nov 16.

20.

Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors.

Tan TZ, Rouanne M, Tan KT, Huang RY, Thiery JP.

Eur Urol. 2019 Mar;75(3):423-432. doi: 10.1016/j.eururo.2018.08.027. Epub 2018 Sep 10.

PMID:
30213523
21.

DNA Methylation Profiling of Breast Cancer Cell Lines along the Epithelial Mesenchymal Spectrum-Implications for the Choice of Circulating Tumour DNA Methylation Markers.

Le AV, Szaumkessel M, Tan TZ, Thiery JP, Thompson EW, Dobrovic A.

Int J Mol Sci. 2018 Aug 28;19(9). pii: E2553. doi: 10.3390/ijms19092553.

22.

Actin Cytoskeleton Remodeling Drives Breast Cancer Cell Escape from Natural Killer-Mediated Cytotoxicity.

Al Absi A, Wurzer H, Guerin C, Hoffmann C, Moreau F, Mao X, Brown-Clay J, Petrolli R, Casellas CP, Dieterle M, Thiery JP, Chouaib S, Berchem G, Janji B, Thomas C.

Cancer Res. 2018 Oct 1;78(19):5631-5643. doi: 10.1158/0008-5472.CAN-18-0441. Epub 2018 Aug 13.

23.

Tricho-rhino-phalangeal syndrome 1 protein functions as a scaffold required for ubiquitin-specific protease 4-directed histone deacetylase 2 de-ubiquitination and tumor growth.

Wang Y, Zhang J, Wu L, Liu W, Wei G, Gong X, Liu Y, Ma Z, Ma F, Thiery JP, Chen L.

Breast Cancer Res. 2018 Aug 2;20(1):83. doi: 10.1186/s13058-018-1018-7.

24.

The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer.

Antony J, Zanini E, Kelly Z, Tan TZ, Karali E, Alomary M, Jung Y, Nixon K, Cunnea P, Fotopoulou C, Paterson A, Roy-Nawathe S, Mills GB, Huang RY, Thiery JP, Gabra H, Recchi C.

EMBO Rep. 2018 Aug;19(8). pii: e45670. doi: 10.15252/embr.201745670. Epub 2018 Jun 15.

25.

Integrated use of bioinformatic resources reveals that co-targeting of histone deacetylases, IKBK and SRC inhibits epithelial-mesenchymal transition in cancer.

Barneh F, Mirzaie M, Nickchi P, Tan TZ, Thiery JP, Piran M, Salimi M, Goshadrou F, Aref AR, Jafari M.

Brief Bioinform. 2019 Mar 25;20(2):717-731. doi: 10.1093/bib/bby030.

PMID:
29726962
26.

CD47 is a direct target of SNAI1 and ZEB1 and its blockade activates the phagocytosis of breast cancer cells undergoing EMT.

Noman MZ, Van Moer K, Marani V, Gemmill RM, Tranchevent LC, Azuaje F, Muller A, Chouaib S, Thiery JP, Berchem G, Janji B.

Oncoimmunology. 2018 Feb 15;7(4):e1345415. doi: 10.1080/2162402X.2017.1345415. eCollection 2018.

27.

Engineered commensal microbes for diet-mediated colorectal-cancer chemoprevention.

Ho CL, Tan HQ, Chua KJ, Kang A, Lim KH, Ling KL, Yew WS, Lee YS, Thiery JP, Chang MW.

Nat Biomed Eng. 2018 Jan;2(1):27-37. doi: 10.1038/s41551-017-0181-y. Epub 2018 Jan 10.

PMID:
31015663
28.

TGFβ Promotes Genomic Instability after Loss of RUNX3.

Krishnan V, Chong YL, Tan TZ, Kulkarni M, Bin Rahmat MB, Tay LS, Sankar H, Jokhun DS, Ganesan A, Chuang LSH, Voon DC, Shivashankar GV, Thiery JP, Ito Y.

Cancer Res. 2018 Jan 1;78(1):88-102. doi: 10.1158/0008-5472.CAN-17-1178. Epub 2017 Oct 26.

29.

Metastatic efficiency of tumour cells can be impaired by intraoperative cell salvage process: truth or conjecture?

Kumar N, Zaw AS, Kantharajanna SB, Khoo BL, Lim CT, Thiery JP.

Transfus Med. 2017 Oct;27 Suppl 5:327-334. doi: 10.1111/tme.12453. Epub 2017 Aug 23. Review.

PMID:
28833768
30.

Molecular characterization of breast cancer CTCs associated with brain metastasis.

Boral D, Vishnoi M, Liu HN, Yin W, Sprouse ML, Scamardo A, Hong DS, Tan TZ, Thiery JP, Chang JC, Marchetti D.

Nat Commun. 2017 Aug 4;8(1):196. doi: 10.1038/s41467-017-00196-1.

31.

New insights into the role of EMT in tumor immune escape.

Terry S, Savagner P, Ortiz-Cuaran S, Mahjoubi L, Saintigny P, Thiery JP, Chouaib S.

Mol Oncol. 2017 Jul;11(7):824-846. doi: 10.1002/1878-0261.12093. Epub 2017 Jun 27. Review.

32.

Clear Cell Renal Cell Carcinoma is linked to Epithelial-to-Mesenchymal Transition and to Fibrosis.

Landolt L, Eikrem Ø, Strauss P, Scherer A, Lovett DH, Beisland C, Finne K, Osman T, Ibrahim MM, Gausdal G, Ahmed L, Lorens JB, Thiery JP, Tan TZ, Sekulic M, Marti HP.

Physiol Rep. 2017 Jun;5(11). pii: e13305. doi: 10.14814/phy2.13305. Erratum in: Physiol Rep. 2018 Apr;6(8):e13671.

33.

The EMT spectrum and therapeutic opportunities.

Voon DC, Huang RY, Jackson RA, Thiery JP.

Mol Oncol. 2017 Jul;11(7):878-891. doi: 10.1002/1878-0261.12082. Epub 2017 Jun 19. Review.

34.

Targeting HSP90-HDAC6 Regulating Network Implicates Precision Treatment of Breast Cancer.

Yu S, Cai X, Wu C, Liu Y, Zhang J, Gong X, Wang X, Wu X, Zhu T, Mo L, Gu J, Yu Z, Chen J, Thiery JP, Chai R, Chen L.

Int J Biol Sci. 2017 Apr 8;13(4):505-517. doi: 10.7150/ijbs.18834. eCollection 2017.

35.

Acquisition of tumor cell phenotypic diversity along the EMT spectrum under hypoxic pressure: Consequences on susceptibility to cell-mediated cytotoxicity.

Terry S, Buart S, Tan TZ, Gros G, Noman MZ, Lorens JB, Mami-Chouaib F, Thiery JP, Chouaib S.

Oncoimmunology. 2017 Jan 17;6(2):e1271858. doi: 10.1080/2162402X.2016.1271858. eCollection 2017.

36.

The Emerging Roles of RUNX Transcription Factors in Epithelial-Mesenchymal Transition.

Voon DC, Thiery JP.

Adv Exp Med Biol. 2017;962:471-489. doi: 10.1007/978-981-10-3233-2_28. Review.

PMID:
28299674
37.

Data-Driven Discovery of Extravasation Pathway in Circulating Tumor Cells.

Yadavalli S, Jayaram S, Manda SS, Madugundu AK, Nayakanti DS, Tan TZ, Bhat R, Rangarajan A, Chatterjee A, Gowda H, Thiery JP, Kumar P.

Sci Rep. 2017 Mar 6;7:43710. doi: 10.1038/srep43710.

38.

Transposon insertional mutagenesis in mice identifies human breast cancer susceptibility genes and signatures for stratification.

Chen L, Jenjaroenpun P, Pillai AM, Ivshina AV, Ow GS, Efthimios M, Zhiqun T, Tan TZ, Lee SC, Rogers K, Ward JM, Mori S, Adams DJ, Jenkins NA, Copeland NG, Ban KH, Kuznetsov VA, Thiery JP.

Proc Natl Acad Sci U S A. 2017 Mar 14;114(11):E2215-E2224. doi: 10.1073/pnas.1701512114. Epub 2017 Mar 1.

39.

The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200.

Noman MZ, Janji B, Abdou A, Hasmim M, Terry S, Tan TZ, Mami-Chouaib F, Thiery JP, Chouaib S.

Oncoimmunology. 2017 Jan 23;6(1):e1263412. doi: 10.1080/2162402X.2016.1263412. eCollection 2017.

40.

'Normalizing' the malignant phenotype of luminal breast cancer cells via alpha(v)beta(3)-integrin.

Abu-Tayeh H, Weidenfeld K, Zhilin-Roth A, Schif-Zuck S, Thaler S, Cotarelo C, Tan TZ, Thiery JP, Green JE, Klorin G, Sabo E, Sleeman JP, Tzukerman M, Barkan D.

Cell Death Dis. 2016 Dec 1;7(12):e2491. doi: 10.1038/cddis.2016.387.

41.

The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer.

Antony J, Tan TZ, Kelly Z, Low J, Choolani M, Recchi C, Gabra H, Thiery JP, Huang RY.

Sci Signal. 2016 Oct 4;9(448):ra97.

42.

PRL3-zumab, a first-in-class humanized antibody for cancer therapy.

Thura M, Al-Aidaroos AQO, Yong WP, Kono K, Gupta A, Lin YB, Mimura K, Thiery JP, Goh BC, Tan P, Soo R, Hong CW, Wang L, Lin SJ, Chen E, Rha SY, Chung HC, Li J, Nandi S, Yuen HF, Zhang SD, Guan YK, So J, Zeng Q.

JCI Insight. 2016 Jun 16;1(9):e87607. doi: 10.1172/jci.insight.87607.

43.

Impact of label-free technologies in head and neck cancer circulating tumour cells.

Kulasinghe A, Kenny L, Perry C, Thiery JP, Jovanovic L, Vela I, Nelson C, Punyadeera C.

Oncotarget. 2016 Nov 1;7(44):71223-71234. doi: 10.18632/oncotarget.12086.

44.

TIP60 inhibits metastasis by ablating DNMT1-SNAIL2-driven epithelial-mesenchymal transition program.

Zhang Y, Subbaiah VK, Rajagopalan D, Tham CY, Abdullah LN, Toh TB, Gong M, Tan TZ, Jadhav SP, Pandey AK, Karnani N, Chow EK, Thiery JP, Jha S.

J Mol Cell Biol. 2016 Sep 20. pii: mjw038. [Epub ahead of print]

PMID:
27651430
45.

An epithelial marker promoter induction screen identifies histone deacetylase inhibitors to restore epithelial differentiation and abolishes anchorage independence growth in cancers.

Tang HM, Kuay KT, Koh PF, Asad M, Tan TZ, Chung VY, Lee SC, Thiery JP, Huang RJ.

Cell Death Discov. 2016 Jun 13;2:16041. doi: 10.1038/cddiscovery.2016.41. eCollection 2016.

46.

Correction: RKIP regulates CCL5 expression to inhibit breast cancer invasion and metastasis by controlling macrophage infiltration.

Datar I, Qiu X, Ma HZ, Yeung M, Aras S, de la Serna I, Al-Mulla F, Tan TZ, Thiery JP, Trumbly R, Xuan F, Cui H, Yeung KC.

Oncotarget. 2016 May 3;7(18):26925. doi: 10.18632/oncotarget.9139.

47.

Liquid biopsy and therapeutic response: Circulating tumor cell cultures for evaluation of anticancer treatment.

Khoo BL, Grenci G, Jing T, Lim YB, Lee SC, Thiery JP, Han J, Lim CT.

Sci Adv. 2016 Jul 13;2(7):e1600274. doi: 10.1126/sciadv.1600274. eCollection 2016 Jul.

48.

Manganese Superoxide Dismutase Expression Regulates the Switch Between an Epithelial and a Mesenchymal-Like Phenotype in Breast Carcinoma.

Loo SY, Hirpara JL, Pandey V, Tan TZ, Yap CT, Lobie PE, Thiery JP, Goh BC, Pervaiz S, Clément MV, Kumar AP.

Antioxid Redox Signal. 2016 Aug 20;25(6):283-99. doi: 10.1089/ars.2015.6524.

49.

EMT: 2016.

Nieto MA, Huang RY, Jackson RA, Thiery JP.

Cell. 2016 Jun 30;166(1):21-45. doi: 10.1016/j.cell.2016.06.028. Review.

50.

Functional characterization of selective exosite-binding inhibitors of matrix metalloproteinase-13 (MMP-13) - experimental validation in human breast and colon cancer.

Kothapalli R, Sivaraman Siveen K, Tan TZ, Thiery JP, Kumar AP, Sethi G, Swaminathan K.

Biosci Biotechnol Biochem. 2016 Nov;80(11):2122-2131. doi: 10.1080/09168451.2016.1200456. Epub 2016 Jun 29.

PMID:
27362887

Supplemental Content

Loading ...
Support Center